OBJECTIVES: Clinical guidelines are available at a national level for the treatment of patients with psoriatic arthritis (PsA) in the Brazilian public health system (SUS). The present research aims to estimate the budget impact of the incorporation of golimumab (GOL) as an additional biological treatment option in these guidelines. METHODS: A budget impact analysis (BIA) was developed using a two health states Markov model (new/first line and discontinued) with annual cycle length. The budget impact of GOL incorporation was compared to the current scenario, from SUS perspective. Target population was defined as patients naïve to biological treatment and estimated based on DATASUS database. A 5-year time horizon was employed, considering population growth according to IBGE statistics. GOL adoption rate was assumed as 40% at the end of 5 years, with annual discontinuation rate of 25%. Once discontinued, it was assumed patients remain in this state until the end of the analysis. Only drug acquisition costs were considered and prices were gathered from the official government website. Annual treatment costs were calculated following doses/intervals defined in the guidelines. Deterministic sensitivity analysis (DSA) was carried to determine the impact of the assumptions on results. RESULTS: